scPharmaceuticals (SCPH)
(Delayed Data from NSDQ)
$5.52 USD
+0.35 (6.77%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $5.52 0.00 (0.00%) 5:42 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, scPharmaceuticals, Inc. has a market cap of $272.93M, which represents its share price of $5.17 multiplied by its outstanding shares number of 52.79M. As a small-cap company, SCPH's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
SCPH 5.52 +0.35(6.77%)
Will SCPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SCPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SCPH
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates
SCPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates
Other News for SCPH
scPharmaceuticals Holds Annual Stockholders Meeting June 2025
scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025
Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (SCPH), 10x Genomics (TXG) and Kura Oncology (KURA)
Craig-Hallum Sticks to Its Buy Rating for scPharmaceuticals (SCPH)
scPharmaceuticals Earnings Call Highlights Growth and Expansion